Browse

S-Space

Browsing by Author Solomon, Benjamin J.

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 19 of 19

Issue Date Title / Author(s) / CitationFileAltmetrics
2010-12
Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer
DOI
2011-05
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
DOI
2011-10
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
DOI
2011-12
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
DOI
2013-06
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
DOI
2014-03
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
DOI
2014-11
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
DOI
2014-12
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona; Boyer, M.; Ganju, V.; Hughes, B.; Pavlakis, N.; Solomon, B.; Varma, S.; Berghmans, T.; Canon, J-L; Demedts, I.; Janssens, A.; Louis, R.; Pieters, T.; Schallier, D.; Surmont, V.; da Silva, C. Maciel; Ferreira, C-G Moreira; Hirsh, V.; Joy, A.; Laberge, F.; Morzycki, W.; Wierzbicki, R.; Han, B.; Liu, X.; Qin, S.; Shi, Y.; Wang, Y.; Wu, G.; Wu, Y-L; Zhou, C.; Ahvonen, J.; Barlesi, F.; Cadranel, J.; Dansin, E.; Fayette, J.; Morere, J-F; Moro-Sibilot, D.; Pujol, J-L; Quoix, E.; Zalcman, G.; Frickhofen, N.; Schneider, C-P; Wehler, T.; Mok, T.; So, P.; Cuffe, S.; Bearz, A.; Boni, C.; Cappuzzo, F.; Cognetti, F.; De Braud, F.; De Pas, T.; Galetta, D.; Migliorino, M.; Rocco, D.; Scagliotti, G.; Tagliaferri, P.; Tiseo, M.; Aoe, K.; Hida, T.; Kato, T.; Kozuki, T.; Nakagawa, K.; Niho, S.; Nishio, M.; Nokihara, H.; Satouchi, M.; Seto, T.; Takahashi, T.; Ahn, J-S; Kim, D-W; Kim, S-W; Berchem, G.; Rodriguez, O. Arrieta; Biesma, B.; Dingemans, A-M; Smit, E.; Helland, A.; Barata, F.; Gorbunova, V.; Manikhas, G.; Orlov, S.; Leong, S.; Lim, H-L; Soo, R.; Tan, E-H; Nosworthy, A.; Villena, M. Codes; Felip, E.; Lopez, P. Garrido; Casado, D. Isla; Banaclocha, N. Martinez; Aix, S. Ponce; Aransay, N. Reguart; Abreu, D. Rodriguez; Perez, J. Trigo; Gautschi, O.; Pless, M.; Zippelius, A.; Chang, G-C; Tsai, Y-H; Shparyk, Y.; Blackhall, F.; Steele, N.; Armenio, V.; Dragnev, K.; Dugan, M.; Gadgeel, S.; Gerber, D.; Graziano, S.; Gurubhagavatula, S.; Horn, L.; Jalal, S.; Lauer, R.; Mehra, R.; Mekhail, T.; Mirshahidi, H.; Pakkala, S.; Polikoff, J.; Raftopoulos, H.; Saleh, M.; Salgia, R.; Waqar, S.

New England Journal of Medicine, Vol.371 No.23, pp.2167-2177

DOI
2016-04
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
DOI
2016-08
Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014
DOI
2017-08
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive nonsmall- cell lung cancer
DOI
2018-07
Crizotinib versus chemotherapy in asian patients with alk-positive advanced non-small cell lung cancer
view fileDOI
2018-08
Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer
DOI
2019-07
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
DOI
2020-11
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
DOI
2021-08
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer
DOI
2022-07
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial
DOI
2022-12
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer
DOI
2022-12
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
DOI
1

Seoul National University Library, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea TEL: 02-880-5567 Email: s-space@snu.ac.kr youtube

RSS 1.0 RSS 2.0 Atom

Hello

Browse

News About S-Space Seoul National University Library LOGIN